Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

<p>Kaplan–Meier plot of (<b>A</b>) PFS and (<b>B</b>) OS. CI, confidence interval; OS, overall survival; PFS, progression-free survival; RECIST v1.1, Response Evaluation Criteria for Solid Tumors version 1.1.</p>

Պահպանված է:

Մատենագիտական մանրամասներ
Հիմնական հեղինակ:	Diwakar Davar (15023480) (author)
Այլ հեղինակներ:	Zeynep Eroglu (19276519) (author), Mohammed Milhem (16527976) (author), Carlos Becerra (22053822) (author), Martin Gutierrez (15360052) (author), Antoni Ribas (14837278) (author), Brian Di Pace (22053016) (author), Tianli Wang (22053019) (author), Hailei Zhang (20634191) (author), Srimoyee Ghosh (22053025) (author), Niranjan Yanamandra (22053022) (author), Theo Borgovan (22053031) (author), Shyam Srivats (22053825) (author), Angela Waszak (22053034) (author), Arindam Dhar (15016280) (author), Patricia LoRusso (15134565) (author)
Հրապարակվել է:	2025
Խորագրեր:	Cancer Cancer Biology Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase I clinical trials Immunotherapy Antibody immunotherapy Checkpoint blockade Lung Cancer Oncogenes & Tumor Suppressors PD-1
Ցուցիչներ:	Ավելացրեք ցուցիչ Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!